Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival.

Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA.

Int J Cancer. 2017 Jul 1;141(1):184-190. doi: 10.1002/ijc.30726. Epub 2017 Apr 21.

2.

Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.

Yagishita S, Horinouchi H, Katsui Taniyama T, Nakamichi S, Kitazono S, Mizugaki H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Sumi M, Shiraishi K, Kohno T, Furuta K, Tsuta K, Tamura T.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):140-8. doi: 10.1016/j.ijrobp.2014.08.344. Epub 2014 Oct 13.

PMID:
25442336
3.

Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.

Lee VH, Tin VP, Choy TS, Lam KO, Choi CW, Chung LP, Tsang JW, Ho PP, Leung DK, Ma ES, Liu J, Shek TW, Kwong DL, Leung TW, Wong MP.

J Thorac Oncol. 2013 Sep;8(9):1148-55. doi: 10.1097/JTO.0b013e31829f684a.

4.

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.

J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.

5.

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).

Lim SM, Kim HR, Cho EK, Min YJ, Ahn JS, Ahn MJ, Park K, Cho BC, Lee JH, Jeong HC, Kim EK, Kim JH.

Oncotarget. 2016 Jun 14;7(24):36311-36320. doi: 10.18632/oncotarget.8904.

6.

Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer.

Yagishita S, Horinouchi H, Sunami KS, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Sumi M, Shiraishi K, Kohno T, Furuta K, Tsuta K, Tamura T, Ohe Y.

Cancer Sci. 2015 Oct;106(10):1402-7. doi: 10.1111/cas.12740. Epub 2015 Aug 18.

7.
8.

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SC, Gershenson DM, Wong KK.

J Pathol. 2013 Dec;231(4):449-56. doi: 10.1002/path.4252.

9.

Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.

Ludovini V, Bianconi F, Pistola L, Pistola V, Chiari R, Colella R, Bellezza G, Tofanetti FR, Siggillino A, Baldelli E, Flacco A, Giuffrida D, Sidoni A, Crinò L.

Cancer Chemother Pharmacol. 2012 May;69(5):1289-99. doi: 10.1007/s00280-012-1829-7.

PMID:
22302407
10.

Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients.

Wang R, Zhang Y, Pan Y, Li Y, Hu H, Cai D, Li H, Ye T, Luo X, Zhang Y, Li B, Shen L, Sun Y, Chen H.

Oncotarget. 2015 Oct 27;6(33):34300-8. doi: 10.18632/oncotarget.5549.

11.

EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.

Lee JS, Kim HR, Lee CY, Shin M, Shim HS.

Ann Surg Oncol. 2013 Sep;20(9):3015-22. doi: 10.1245/s10434-013-2937-2. Epub 2013 Mar 23.

PMID:
23525704
12.

A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer.

Hernández-Prieto S, Romera A, Ferrer M, Subiza JL, López-Asenjo JA, Jarabo JR, Gómez AM, Molina EM, Puente J, González-Larriba JL, Hernando F, Pérez-Villamil B, Díaz-Rubio E, Sanz-Ortega J.

Clin Transl Oncol. 2015 Apr;17(4):330-8. doi: 10.1007/s12094-014-1235-1. Epub 2014 Oct 10.

PMID:
25301404
13.

Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.

Locatelli-Sanchez M, Couraud S, Arpin D, Riou R, Bringuier PP, Souquet PJ.

Lung. 2013 Oct;191(5):491-9. doi: 10.1007/s00408-013-9482-4. Epub 2013 Jun 9.

PMID:
23749122
14.

EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.

Varella-Garcia M, Mitsudomi T, Yatabe Y, Kosaka T, Nakajima E, Xavier AC, Skokan M, Zeng C, Franklin WA, Bunn PA Jr, Hirsch FR.

J Thorac Oncol. 2009 Mar;4(3):318-25. doi: 10.1097/JTO.0b013e31819667a3.

15.

Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.

Alegre E, Fusco JP, Restituto P, Salas-Benito D, Rodríguez-Ruiz ME, Andueza MP, Pajares MJ, Patiño-García A, Pio R, Lozano MD, Gúrpide A, Lopez-Picazo JM, Gil-Bazo I, Perez-Gracia JL, Gonzalez A.

Tumour Biol. 2016 Oct;37(10):13687-13694. Epub 2016 Jul 29.

PMID:
27473086
16.

Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma.

Lee YJ, Park IK, Park MS, Choi HJ, Cho BC, Chung KY, Kim SK, Chang J, Moon JW, Kim H, Choi SH, Kim JH.

J Cancer Res Clin Oncol. 2009 Dec;135(12):1647-54. doi: 10.1007/s00432-009-0611-7. Epub 2009 Jun 11.

PMID:
19517135
17.

Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.

Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Piattoni S, Di Carlo L, Semeraro A, Darwish S, Tofanetti FR, Stocchi L, Mihaylova Z, Bellezza G, Del Sordo R, Daddi G, Crinò L, Tonato M.

J Thorac Oncol. 2008 Apr;3(4):365-73. doi: 10.1097/JTO.0b013e318168c7d0.

18.

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.

van der Wekken AJ, Kuiper JL, Saber A, Terpstra MM, Wei J, Hiltermann TJN, Thunnissen E, Heideman DAM, Timens W, Schuuring E, Kok K, Smit EF, van den Berg A, Groen HJM.

PLoS One. 2017 Aug 30;12(8):e0182885. doi: 10.1371/journal.pone.0182885. eCollection 2017.

19.

PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.

Wang L, Hu H, Pan Y, Wang R, Li Y, Shen L, Yu Y, Li H, Cai D, Sun Y, Chen H.

PLoS One. 2014 Feb 12;9(2):e88291. doi: 10.1371/journal.pone.0088291. eCollection 2014.

20.

Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: An effort to explore new drug targets.

Veldore VH, Patil S, Satheesh CT, Shashidhara HP, Tejaswi R, Prabhudesai SA, Krishnamoorthy N, Hazarika D, Naik R, Rao RM, Ajai Kumar BS.

Indian J Cancer. 2015 Apr-Jun;52(2):243-8. doi: 10.4103/0019-509X.175843.

Supplemental Content

Support Center